U.S. Influenza Market | Competitive Intelligence 2013 to 2017 | Forecast 2018 to 2024



U.S. Influenza Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024


The U.S. Influenza market is growing at a significant CAGR due to rise in new born babies, and increase in geriatric population. Increase in vaccination awareness, favourable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.


A sample of this report is available upon request @




The U.S. Influenza market is segmented on the basis of product type, distribution channel, and end user


Based on drug class, U.S. influenza market is segmented into the following:

  • Anti-viral drugs
  • Zanamivir
  • Oseltamivir
  • Amantadine
  • Rimantadine
  • Others
  • Interferons
  • Vaccines
  • Trivalent
  • Quadrivalent


Based on the route of administration, U.S. influenza market is segmented into the following:

  • Oral
  • Parenteral
  • Others


Based on distribution channel U.S. influenza market is segmented into the following:

  • Hospital pharmacies
  • Retail pharmacies
  • Others


To view TOC of this report is available upon request @



Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. Launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Sequires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market.


Need more information about this report @




U.S. holds a dominant share in the ****** influenza market. The largest share is attributed to the higher rate of in-vitro diagnostics availability and technological advancements in medical devices which are primarily driving the U.S. Influenza market growth. As per CDC, persons above 6 months of age could be vaccinated to prevent the influenza infection. Increase in prevalence and incidence cases of influenza (According to CDC, about 5 to 20 percent of the U.S. people are infected with influenza in every year. CDC also states that about 200,000 people hospitalized and more than 36,000 people are dying from influenza in U.S) might increase the growth of U.S. influenza market. Similarly, upsurge in funding by the government is also driving the market growth in the United States. The U.S. government awarded 5-year contracts for more than US$ 1 Bn to five drug manufacturers developing technology for speedier mass production of influenza vaccines


Some of the players in U.S. influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Seqirus (U.K.), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc (U.S.)., Alvogen (South Korea), Medimmune Inc. (U.S.), DynPort Vaccine Company, LLC. (U.S.), and Abbott Laboratories (U.S.) to name a few.


Get access to full summary @




About Precision Business Insights


Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.


Contact to Precision Business Insights,


Kemp House,

152 – 160 City Road,

London EC1V 2NX


Email: sales@precisionbusinessinsights.com


Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.